close
Add to watchlist
Depomed Inc (DEPO) Healthcare, Biotechnology & Drugs
Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States, Canada, and Korea; and Proquin XR for treatment of uncomplicated urinary tract infection in the United States. The company's under development products comprise DM-5689, a Phase III clinical trial product for the treatment of menopausal hot flashes; DM-1796, a Phase III clinical trial product for the treatment of postherpetic neuralgia, as well as is in Phase II clinical trail for diabetic peripheral neuropathy; DM-3458, a Phase I clinical trial product for the treatment of gastroesophageal reflux disease; and DM-1992, a Phase I clinical trial product that targets Parkinson's disease. It has collaboration and license agreements with PharmaNova, Inc.; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Covidien Ltd.; Santarus, Inc.; Teva Pharmaceuticals USA, Inc.; Patheon, Inc.; Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; Watson Pharmaceuticals, Inc.; and Rottapharm/Madaus S.r.l. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is based in Menlo Park, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 5.97 |
| Volume | 373506 |
| Volume Avg | 484248 |
| 52 Week High | 10.19 |
| 52 Week Low | 4.20 |
| PE | 4.82 |
| PE (group average) | 39 |
| EPS Year | 1.26 |
| EPS change Q/Q | 6066.67% |
| EPS change Q/Q Yr ago | -1000% |
| EPS change Q/Q next Q est | -1000% |
| EPS change Y/Y | 1000% |
| REV change Q/Q | 297.61% |
| REV change Q/Q Yr ago | 439.61% |
| EPS next Q est | -0.22 |
| EPS next Y est | -0.03 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |